EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Annexon's Enterprise Value is $212.19 Mil.
Annexon's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-131.05 Mil. Therefore, Annexon's EV-to-EBIT for today is -1.62.
The historical rank and industry rank for Annexon's EV-to-EBIT or its related term are showing as below:
ANNX'
s EV-to-EBIT Range Over the Past 10 Years
Min: -8.01 Med: 0 Max: 1.01
Current: -1.59
During the past 6 years, the highest EV-to-EBIT of Annexon was 1.01. The lowest was -8.01. And the median was 0.00.
ANNX's EV-to-EBIT is ranked worse than 100% of 426
companies
in the Biotechnology industry
Industry Median: 9.975
vs ANNX: -1.59
The historical data trend for Annexon's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Annexon's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annexon's EV-to-EBIT Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annexon's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Annexon's EV-to-EBIT falls into.
Annexon's current Enterprise Value is $212.19 Mil.
Annexon's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon (NAS:ANNX) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Annexon's Enterprise Value for the quarter that ended in Mar. 2024 was $414.59 Mil.
Annexon's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-131.05 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Annexon EV-to-EBIT Related Terms
Thank you for viewing the detailed overview of Annexon's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Annexon's product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; and ANX009, for systemic autoimmune diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ANNX has been successfully added to your 